gilead report sales/earn provid busi updat
investor afternoon compani miss opco consensu expect
sale non-gaap earn respect total sale
product revenu miss see exhibit consist season weak
sale due rebat discount etc aggrav inventori
decreas q/q gener competit eu increas competit hcv
reiter guidanc remain bullish newli launch product
yescarta biktarvi pipelin updat remain track filgotinib phase
readout finch bud nash franchis becom critic
sales/earn number sub-optim see littl caus newfound
concern stay neutral
point earn expect large-cap biotech
high product sale skew yearli sale
last three year sinc line
peer worsen variou one-off factor expect strengthen
sale go forward make minor adjust estim
launch biktarvi bic/f/taf februari track well
prescript come new patient one-third came genvoya
two-third regimen includ approxim regimen
contain dolutegravir compet gsk regimen view market share gain
dolutegravir-bas regimen especi encourag
yescarta sale consensu expect
forti center author april vs februari
earn call despit approv today second car-t therapi dlbcl
novarti kymriah rais yescarta sale expect
consensu
nonpluss question hcv recent commentari
script trend see preview make us comfort
sale number point hcv
consensu last bbg like need come
final
pipelin product molecul filgotinib bud nash
franchis shape critic year next leg mid-term
growth current valuat continu pipelin newsflow
acceler sales/earn remain qs trough year sales/
earn believ overreact arbitrag
medicin area unmet medic
need gilead portfolio product
pipelin investig drug
includ treatment hiv/aid liver
inflammatori
respiratori diseas cardiovascular
analyst certif import disclosur see disclosur
initi coverag gilead perform rate
sinc launch hcv product late
share roller coaster ride
street first underappreci potenti hcv
surpris franchis declin worst-off patient
cure hcv busi stabilizng near term resurg
hiv busi growth addit kite axi-cel nash
off-set flat sales/non-gaap ep
opco model averag rel peer-group metric
believ risk/reward balanc
hcv sale declin slowli stabil
hiv busi launch taf-bas regimen bic/f/taf
make hiv solid growth busi
yescarta axi-cel launch across us eu meet
expect sale
nash franchis lead product selonsertib approv
market
cardiovascular/oth busi sale reduc
due gener competit
non-gaap oper margin declin
filgotinib phase data ra
phase data nash yescarta year follow
data
phase data cle sjogren
selonsertib phase data nash
data nash
complet list catalyst exhibit
hcv sale trough next one two year stable/up
patient diagnos treat
hiv busi outperform expect
axi-cel us/eu launch beat reduc expect provid
abl start grow margin onward
hcv busi continu declin precipit rate near
hiv busi growth minim best next two five year
axi-cel us/eu launch underperform reduc expect due
car-t side-effect manufactur reimburs concern
nash franchis gain traction clinic data
mediocr best even among nash patient fibrosi
statement oper million except per opcovariancenet product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share hcv hiv total products- selonsirtib- total total product inc
exhibit on-going switch descovy-contain hiv regimen us
compani present million
compani present cdc ipso healthcar hiv us therapi monitor/scop estimate patient thousand
exhibit hcv patient initi sofosbuvir-bas regimen
compani present patient thousand
compani present million except per share amount percentag
indicationdrugtimingmilestonehivbiktarvi approvalvesatolimod phase studi hiv phase studi prephematology/oncologyyescarta axicabtagen eu aggress enrol phase enrol phase indol follow data phase adult enrol phase mcliniti phase pediatr initi phase studi phase studi anti-bcma car-t mmdecis registr studi base phase phase studi mage solid ind tcr target solid endpoint phase combo studi r/r cllotherremdesivir phase studi ebola survivorsnash pbc psc enrol stellar phase studi fxr data futil analysi phase studi uccomplet phase studi ankylos spondylitiscomplet phase studi psoriat phase finch studi phase finch studi phase finch studi divers studi enrol crohn phase studi cutan lupu erythematosusdata phase studi sjogren syndrom inc
vosevi- hcv vemlidy- bic/ftc/taf- hiv total axi-cel- selonsirtib- total total product perform na
statement million except per product royalti contract total good research sell gener non-gaap oper non-gaap oper non-gaap incom expens interest non-gaap incom incom incom tax non-gaap net net loss attribut non control net incom attribut dilut dilut share adjust comp gross oper incom tax inc
bloomberg price
